RxDoctor Payments Data

Mia Romanelli, PA

Physician Assistant · Naples, FLNPI 1780356709

Payments from drug & device makers

$3,189in general payments, 2019–2025

Across 161 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$772
  • Johnson & Johnson$381
  • Boehringer Ingelheim$327
  • Amgen$285
  • Bayer$264
  • Alnylam Pharmaceuticals Inc.$257
  • plus $902 from 14 others

What the payments were for

  • Food & beverage$3,186100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,189 in reported general payments places this provider in the 80th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$47,991
Medicare patients
387
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis30$670,305
EliquisApixaban136$178,353
Repatha SureclickEvolocumab166$126,928
EntrestoSacubitril/Valsartan48$74,627
XareltoRivaroxaban46$57,171
JardianceEmpagliflozin42$46,392
Praluent PenAlirocumab37$24,119
Metoprolol Succinate321$6,144
Losartan Potassium328$4,345
Amlodipine Besylate358$3,402
Telmisartan88$2,823
Atorvastatin Calcium252$2,612
Rosuvastatin Calcium147$2,144
Ezetimibe57$1,985
Nebivolol Hcl50$1,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$253$848,658166 claims
NovartisEntresto$772$74,62748 claims
Johnson & JohnsonXarelto$381$57,17146 claims
Boehringer IngelheimJardiance$327$46,39242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →